Type 2 Diabetes
Patients with both Parkinson disease and type 2 diabetes were more likely to have cardiovascular comorbidities than those with only Parkinson disease.
Access to ready-to-eat outlets that sell food for instant consumption is associated with greater risk for type 2 diabetes.
Intensive blood pressure control and fenofibrate use in patients with type 2 diabetes who are at high risk for cardiovascular disease may increase the risk for adverse kidney events.
Gastric banding and metformin resulted in similar improvements in insulin sensitivity in moderately obese adults with impaired glucose tolerance or mild T2D over a 2-year period.
Researchers found that higher levels of fatty acid biomarkers 15:0, 17:0, and trans-16:1n7 were inversely associated with risk for T2D.
Researchers analyzed how improvements in metabolic syndrome may impact the risk of developing type 2 diabetes and cardiovascular disease in patients with prediabetes.
For this analysis, the authors used follow-up data from all 7020 patients included in the EMPA-REG OUTCOME trial to estimate the effect of empagliflozin on all-cause mortality vs placebo over the duration of a patient's lifetime.
Recommendations for the management of type 2 diabetes have been updated, according to a consensus report by the American Diabetes Association and the European Association for the Study of Diabetes.
Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria.
SGLT-2i exhibited superior effects in terms of weight loss and did not increase the risk for hypoglycemia in dual therapy with sulfonylurea.
Racial/ethnic differences seen in the association of aldosterone with incident type 2 diabetes.
WHO has developed guidelines for selecting therapy for treatment intensiﬁcation in type 2 diabetes and on the use of insulin in type 1 and 2 diabetes in resource-poor settings.
Investigators aimed to assess the effect of psychotropic medications, BMI, duration of schizophrenia, number of hospitalizations, and physical activity on the risk for T2D.
Benefit seen for adoption of healthy lifestyle even after T2DM diagnosis made.
Patients who received gastric bypass surgery had lower rates of diabetic neuropathy at follow up that remained stable throughout the study.
The early diagnosis and management of prediabetes will have a significant impact on patient outcomes and healthcare spending.
In this retrospective cohort study, for patients with type 2 diabetes, initiation of a basal insulin analog compared with NPH insulin was not associated with a reduced risk of hypoglycemia-related ED visits or hospital admissions.
Investigators compared low-carbohydrate with low-fat diet on glucose control and other metabolic and anthropometric variables in T2D.
Circulating hepatic markers may predict the risk for diabetes in women.
This represents the prospective study confirming an independent relationship between cardiovascular mortality and oxidative DNA damage in type 2 diabetes.
Compared with human neutral protamine Hagedorn insulin, basal insulin analogs do not reduce risk of hypoglycemia-linked ED visits or hospital admissions in T2D.
The relationship between bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Investigators analyzed real world data to examine the risk for below-knee amputations in patients with type 2 diabetes taking canagliflozin vs other medications.
Investigators examined the effectiveness of oral agents vs insulin as an initial treatment option for people newly diagnosed with type 2 diabetes.
Investigators examined the efficacy of liraglutide for the prevention of dementia in elderly patients with type 2 diabetes.
Investigators examined the prevalence of chronic kidney disease in adults with type 1 diabetes compared with type 2 diabetes.
MEDI0382 reduced body weight and normalized fasting and postprandial blood glucose levels in patients with type 2 diabetes.
Investigators examined the incidence and outcomes of pneumonia in patients with acute ischemic stroke and type 2 diabetes.
Increased risk of subsequent diabetes independent of traditional diabetes risk factors
Per-person diabetes-attributable costs ranged from 374 in New Mexico to 1,610 in Washington, D.C.